Home
Trials
FAQ
Drugs
Centers
Events
About us
More
#ASCO22 Myeloma Abstracts - 2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL
#EHA2022 - Myeloma Abstracts - EHA2022 Congress: June 9 - 12, 2022 - Vienna, Austria
#COMY22 - Myeloma Abstracts - COMy World Congress Paris, France - May 12-15, 22
IMF - International Myeloma Foundation: Patient Handbook 2022
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
FDA Approved for RRMM:Daratumumab and Hyaluronidase-fihj(Darzalex Faspro) + Kyprolis & Dexamethasone
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma - NUTRIVENTION
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
What is Multiple Myeloma? - Drs. Landgren and Gertz HealthTree University Myeloma
NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.